Atopic Dermatitis: Determining Utilization Management Criteria for Long-Term Systemic Therapies

2016-12-19 18:29:00
Tags: Atopic Dermatitis,Crisaborole,pediatric eczema,psoriasis,severe Atopic Dermatitis,Ustekinumab,specialty pharmacy

Panelists Peter L. Salgo, MD; Jonathan Silverberg, MD, PhD, MPH; Jeffrey D. Dunn, PharmD, MBA; Cheryl Allen, BS Pharm, MBA; and Ed Pezalla, MD, MPH, discuss determining and recognizing utilization management for long-term systemic therapies in patients with atopic dermatitis.